309 related articles for article (PubMed ID: 19740344)
1. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.
Mu L; Sun B; Kong Q; Wang J; Wang G; Zhang S; Wang D; Liu Y; Liu Y; An H; Li H
Immunology; 2009 Sep; 128(1 Suppl):e826-36. PubMed ID: 19740344
[TBL] [Abstract][Full Text] [Related]
2. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile.
Yang H; Zhang Y; Wu M; Li J; Zhou W; Li G; Li X; Xiao B; Christadoss P
Inflamm Res; 2010 Mar; 59(3):197-205. PubMed ID: 19768385
[TBL] [Abstract][Full Text] [Related]
3. ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles.
Xie X; Mu L; Yao X; Li N; Sun B; Li Y; Zhan X; Wang X; Kang X; Wang J; Liu Y; Zhang Y; Wang G; Wang D; Liu X; Kong Q; Li H
Clin Immunol; 2013 Aug; 148(2):162-76. PubMed ID: 23773919
[TBL] [Abstract][Full Text] [Related]
4. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines.
Li XL; Liu Y; Cao LL; Li H; Yue LT; Wang S; Zhang M; Li XH; Dou YC; Duan RS
Mol Cell Neurosci; 2013 Sep; 56():85-95. PubMed ID: 23541702
[TBL] [Abstract][Full Text] [Related]
6. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.
Aricha R; Mizrachi K; Fuchs S; Souroujon MC
J Autoimmun; 2011 Mar; 36(2):135-41. PubMed ID: 21193288
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.
Yao X; Kong Q; Xie X; Wang J; Li N; Liu Y; Sun B; Li Y; Wang G; Li W; Qu S; Zhao H; Wang D; Liu X; Zhang Y; Mu L; Li H
Immunology; 2014 Nov; 143(3):396-405. PubMed ID: 24850614
[TBL] [Abstract][Full Text] [Related]
8. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR.
Zhang GX; Xiao BG; Yu LY; van der Meide PH; Link H
J Neuroimmunol; 2001 Feb; 113(1):10-8. PubMed ID: 11137572
[TBL] [Abstract][Full Text] [Related]
10. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
11. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
Im SH; Barchan D; Maiti PK; Raveh L; Souroujon MC; Fuchs S
FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
[TBL] [Abstract][Full Text] [Related]
12. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO.
Kong QF; Sun B; Wang GY; Zhai DX; Mu LL; Wang DD; Wang JH; Li R; Li HL
Eur J Immunol; 2009 Mar; 39(3):800-9. PubMed ID: 19283707
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis.
Aricha R; Feferman T; Fuchs S; Souroujon MC
J Immunol; 2008 Feb; 180(4):2132-9. PubMed ID: 18250419
[TBL] [Abstract][Full Text] [Related]
15. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta.
Kong QF; Sun B; Bai SS; Zhai DX; Wang GY; Liu YM; Zhang SJ; Li R; Zhao W; Sun YY; Li N; Wang Q; Peng HS; Jin LH; Li HL
J Neuroimmunol; 2009 Feb; 207(1-2):83-91. PubMed ID: 19174310
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis.
Cui YZ; Qu SY; Chang LL; Zhao JR; Mu L; Sun B; Li HL; Zhang TS; Wang GY; Kong QF
Neurosci Bull; 2019 Jun; 35(3):507-518. PubMed ID: 30796753
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells.
Liu Y; Yang CL; Yang B; Du T; Li XL; Zhang P; Ge MR; Lian Y; Li H; Liu YD; Duan RS
Int Immunopharmacol; 2021 Jul; 96():107511. PubMed ID: 33915521
[TBL] [Abstract][Full Text] [Related]
18. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity.
Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H
Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289
[TBL] [Abstract][Full Text] [Related]
19. Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells.
Aricha R; Reuveni D; Fuchs S; Souroujon MC
J Autoimmun; 2016 Feb; 67():57-64. PubMed ID: 26489998
[TBL] [Abstract][Full Text] [Related]
20. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
